Biocon Limited has informed the Exchange regarding 'Company Statement'.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biocon Pharma Limited, a subsidiary of Biocon Limited, has received approval from Health Canada for micafungin for injection, USP, in 50 mg and 100 mg dosages. The drug is used to treat various Candida infections including candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses in adults and children aged four months and older. It is also approved for esophageal candidiasis treatment and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. The approval adds to Biocon's integrated biosimilars and generics portfolio.
The Health Canada approval opens a new market for Biocon's antifungal drug in Canada, strengthening its global generics and biosimilars presence, which could contribute positively to future revenues.